Phase I study of delivery of autologous bone marrow derived mononuclear cells to myopathic right ventricle in patients with Ebstein anomaly during surgical intervention
Research Grant Recipient: Kimberly Holst, MD
Grant Period: 2016-2018
Award Value: $500,000
Site: Mayo Clinic
In no-cost extension to enroll additional patients in study
The goal of this Phase I study is to establish the safety and feasibility of intramyocardial injection of autologous bone marrow derived mononuclear cells (BM-MNC) into the myopathic right ventricle of patients with Ebstein anomaly (EA) at time of elective cardiac surgery.
Dr. Holst is a general and thoracic surgery resident at Mayo Clinic and a resident in the Clinician Investigator Training Program.